Kinlay Scott, Young Melissa M, Gagnon David R
Veterans Affairs Boston Healthcare System, West Roxbury, MA, USA.
Harvard Medical School, Boston, MA, USA.
Am J Prev Cardiol. 2024 Aug 15;19:100718. doi: 10.1016/j.ajpc.2024.100718. eCollection 2024 Sep.
The impact of smoking cessation on long-term clinical outcomes after contemporary percutaneous coronary intervention (PCI) is not well known. We estimated the association of smoking and smoking cessation on the 10-year risk of cardiovascular and non-cardiovascular events in patients after contemporary PCI in a multicenter retrospective cohort of all patients having PCI with second generation drug-eluting stents in the VA Healthcare System between 2008 and 2016. Smoking status, comorbidities and clinical outcomes were extracted from the medical record and the National Death Index. Hazard ratios and 95 % confidence intervals (HR, 95 %CI) were derived from Cox Proportional Hazards Models. Estimates of events prevented from smoking cessation were derived from the differences in absolute risks between subjects who smoked and had stopped smoking. Among 29,001 patients, 10,598 (36.5 %) were current smoking patients, 13,093 (45.1 %) were former smoking patients, and 5,310 (18.3 %) never smoked. Over 10 years, 7,806 (26.9 %) subjects died with non-cardiovascular deaths exceeding cardiovascular deaths. In multivariable models, current smoking was significantly associated with increased long-term risks of all-cause death (HR = 1.27, 95 %CI = 1.19, 1.36), myocardial infarction (HR = 1.32, 95 %CI = 1.21-1.43), cancer death (HR = 2.55, 95 % CI = 2.10, 3.08), and pulmonary death (HR = 4.07, 95 % CI = 2.85, 5.83). Smoking cessation may prevent 18.5 % (95 %CI = 16.0 %, 20.9 %) all-cause deaths, 14.8 % (95 %CI = 9.8 %, 19.6 %) cardiovascular deaths, 42.6 % (95 %CI = 37.7 %, 47.2 %) cancer deaths, and 48.3 % (95 %CI = 41.8 %, 54.2 %) pulmonary deaths among smokers. Stopping smoking will likely have major impacts on non-cardiovascular events as well as cardiovascular events in patients after PCI with second generation drug-eluting stents.
戒烟对当代经皮冠状动脉介入治疗(PCI)后长期临床结局的影响尚不明确。我们在一个多中心回顾性队列中,评估了2008年至2016年间在退伍军人医疗保健系统中接受第二代药物洗脱支架PCI治疗的所有患者中,吸烟及戒烟与10年心血管和非心血管事件风险的关联。从病历和国家死亡指数中提取吸烟状况、合并症及临床结局。风险比和95%置信区间(HR,95%CI)由Cox比例风险模型得出。戒烟预防事件的估计值来自吸烟与已戒烟者绝对风险的差异。在29,001例患者中,10,598例(36.5%)为当前吸烟者,13,093例(45.1%)为既往吸烟者,5,310例(18.3%)从不吸烟。10年间,7,806例(26.9%)患者死亡,非心血管死亡超过心血管死亡。在多变量模型中,当前吸烟与全因死亡(HR = 1.27,95%CI = 1.19, 1.36)、心肌梗死(HR = 1.32,95%CI = 1.21 - 1.43)、癌症死亡(HR = 2.55,95%CI = 2.10, 3.08)和肺部死亡(HR = 4.07,95%CI = 2.85, 5.83)的长期风险显著相关。戒烟可能预防吸烟者中18.5%(95%CI = 16.0%,20.9%)的全因死亡、14.8%(95%CI = 9.8%,19.6%)的心血管死亡、42.6%(95%CI = 37.7%,47.2%)的癌症死亡和48.3%(95%CI = 41.8%,54.2%)的肺部死亡。对于接受第二代药物洗脱支架PCI治疗的患者,戒烟可能对非心血管事件以及心血管事件产生重大影响。